arrow
C

Christoph Springfeld

national center for tumor diseases
H指数:41
被引数:7,892

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268)

碳离子放射治疗非转移性胰腺癌:前瞻性II期PACK研究(NCT04194268)的最终结果

2026-10-220
OAAI
Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)

前瞻性、非干预性队列研究方案:评估经颈静脉肝内门体分流术在初次接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中的获益(NISTIPS TRITICC-4,IKF092)

2026-10-200
OA
Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database

ivosidenib在IDH1突变胆道癌中的真实世界疗效:一项多中心回顾性分析并与TrinetX数据库的比较

2026-04-200
OAAI
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

Reptrectinib治疗NTRK融合阳性的晚期实体瘤: 1/2期试验

2026-02-040
OA
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer
2025-12-010
OA
Clinical practice and implications of biomarker testing in biliary tract cancer: an observational study☆

胆道癌中生物标志物检测的临床实践与意义:一项观察性研究☆

2025-11-040
OAAI
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

在转移性乳腺癌中实施精准肿瘤学:全面基因组分析的临床影响——CATCH研究经验

2025-10-310
OAAI
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

方案:粪菌移植在肝癌中克服阿替利珠单抗/贝伐珠单抗耐药的多中心、随机、安慰剂对照、双盲II期试验(FLORA试验)

2025-09-090
OAAI
Stereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer

碳离子立体定向放疗作为原发性肝癌患者的局部消融治疗

2025-02-180
OAAI
Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study

多组学分析在胆管癌中的应用,以推动DKFZ/NCT/DKTK MASTER研究中的科学进展

2024-09-010
PRE
Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma
2024-08-202
OAAI
Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial
2024-06-010
OAAI